Clinical Trial Update: Phase I Trial of Defactinib and VS-6766. [Phase 1]

View source ↗

Summary

A Phase I clinical trial evaluating the combination of defactinib and VS-6766 across multiple solid tumors, including non-small cell lung cancer and low-grade s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrioid Carcinoma
• Low-grade Serous Ovarian Cancer
• Non-small Cell Lung Cancer
• Pancreatic Cancer

Drugs mentioned

• Defactinib (defactinib)
• VS-6766 (VS-6766)

Snippet

Sponsor: Institute of Cancer Research, United Kingdom | Conditions: NSCLC, Low Grade Serous Ovarian Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING